CIK 0001875558
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Nuvectis Pharma, Inc.
Sign in to watch- Ticker
- NVCT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 862405608
- Phone
- +1 360-837-7232
- Business address
- 1 BRIDGE PLAZA, SUITE 275, FORT LEE, NJ, 07024
- 4 Open-market buy Chairman & CEO bought 260 shares at an average $15.52 ($4,035)
- 4 Open-market buy 10% owner bought 3,285 shares at $15.09 ($49,571)
- 4 Open-market buy 10% owner bought 10,000 shares at $15.36 ($153,600)
- 4 Open-market buy 10% owner bought 8,948 shares at $15.19 ($135,920)
- 4 Open-market buy 10% owner bought 3,179 shares at $15.01 ($47,717)
- 4 Open-market buy Chairman & CEO bought 320 shares at $14.88 ($4,762)
- 4 Open-market buy 10% owner bought 1,176 shares at $15.52 ($18,252)
- 4 Open-market buy 10% owner bought 16,760 shares at $16.46 ($275,870)
- 4 Open-market buy Chairman & CEO bought 750 shares at $16.50 ($12,375)
- 4 Open-market buy 10% owner bought 73,175 shares at $17.43 ($1,275,440)
- 4 Open-market buy 10% owner bought 13,090 shares at an average $17.72 ($231,964)
- 4 Open-market buy Chairman & CEO bought 500 shares at $17.88 ($8,940)
- 4 Open-market buy 10% owner bought 12,700 shares at $17.75 ($225,425)
- 4 Grant or award Director acquired 18,000 shares (grant or award)
- 4 Grant or award Director acquired 18,000 shares (grant or award)
- 4 Grant or award Director acquired 18,000 shares (grant or award)
- 4 Open-market buy 10% owner bought 32,124 shares at an average $17.71 ($568,848)
- 4 Open-market buy Chairman & CEO bought 350 shares at an average $17.45 ($6,108)
- 4 Open-market buy Chairman & CEO bought 330 shares at $17.28 ($5,702)
- 4 Open-market buy Chairman & CEO bought 200 shares at $17.49 ($3,498)
Page 4 of 7 · 139 filings